Merck KGaA R&D Head: Biomarker Approach 'Further Validated' At ASCO

05 Jun 2018

• By Sten Stovall

Luciano Rossetti says Germany's Merck is likely to partner M7824 bifunctional immunotherapy, and go solo with tepotinib.

Tumor marker — Merck KGaA is using biomarkers to select patients for testing Tepotinib and M7824. • Source: Shutterstock

Merck KGAA created an excited stir at ASCO with impressive presentations on its targeted tepotinib and its M7824 TGF-beta trap therapies in non-small cell lung cancer. Its biopharma R&D head tells Scrip the German group wants to develop and commercialize the former on its own, and partner M7824 with a big pharma.

At this year's American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Darmstadt-based Merck unveiled early data from its Phase II VISION trial showing promising initial results using tepotinib...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Merck & Co/Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

29 May 2025

• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

29 May 2025

• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

All Over For iTeos But Applause For Plan To Return Cash Fast

29 May 2025

• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

28 May 2025

• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.